晚期胃癌的维持治疗

doi:10.3760/cma.j.issn.1673-422X.2019.07.011

摘要/Abstract

摘要： 目前替吉奥和卡培他滨是晚期胃癌较为理想的维持治疗药物；在运用免疫及靶向药物维持治疗晚期胃癌的临床试验中，伊匹单抗未能取得阳性结果，雷莫芦单抗尚未取得研究数据，曲妥珠单抗、贝伐珠单抗及阿维单抗的维持治疗试验方案都显示出了初步的有效性；中医药疗法在维持治疗中显示出一定的有效性，仍需进一步研究。

关键词: 胃肿瘤, 药物疗法, 维持治疗

Abstract: S-1 and capecitabine are relatively ideal agents for maintenance treatment of advanced gastric cancer. In clinical trials of using immune and targeted drugs for maintenance treatment of advanced gastric cancer, ipilimumab fails to obtain positive results, ramucirumab has not obtained research data, and trial regimens of maintenance treatment with trastuzumab, bevacizumab and avelumab have all shown initial efficacy. Traditional Chinese medicine therapy has shown some effectiveness in maintenance treatment, which still needs further researches.

Key words: Stomach neoplasms, Drug therapy, Maintenance treatment

姚杨，贾英杰，邓仁芬，李小江，孔凡铭. 晚期胃癌的维持治疗[J]. 国际肿瘤学杂志, 2019, 46(7): 439-442.

Yao Yang, Jia Yingjie, Deng Renfen, Li Xiaojiang, Kong Fanming. Maintenance treatment for advanced gastric cancer[J]. Journal of International Oncology, 2019, 46(7): 439-442.

参考文献

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394424. DOI: 10.3322/caac.21492. ［2］ Li W, Zhao X, Wang H, et al. Maintenance treatment of Uracil and Tegafur (UFT) in responders following firstline fluorouracilbased chemotherapy in metastatic gastric cancer: a randomized phase Ⅱ study［J］. Oncotarget, 2017, 8(23): 3782637834. DOI: 10.18632/oncotarget.13922. ［3］中华人民共和国国家卫生健康委员会. 胃癌诊疗规范(2018年版)［J］. 肿瘤综合治疗电子杂志, 2019, 5(1): 5582. DOI: 10.12151/JMCM.2019.0108. ［4］ Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives［J］. World J Gastroenterol, 2016, 22(8): 24032414. DOI: 10.3748/wjg.v22.i8.2403. ［5］刘捷, 林榕波, 范南峰. 老年晚期胃癌替吉奥维持治疗疗效及预后分析［J］. 中华肿瘤防治杂志, 2018, 25(1): 4550. ［6］ He MM, Wang F, Jin Y, et al. Phase Ⅱ clinical trial of S1 plus nanoparticle albuminbound paclitaxel in untreated patients with metastatic gastric cancer［J］. Cancer Sci, 2018, 109(11): 35753582. DOI: 10.1111/cas.13813. ［7］ Pfeiffer P, Qvortrup C, Krogh M, et al. S1 in combination with docetaxel and oxaliplatin in patients with advanced gastroesophageal adenocarcinoma: two parallel phase 1/2a studies［J］. Acta Oncol, 2017, 56(1): 4651. DOI: 10.1080/0284186X.2016.1257865. ［8］ Haag GM, Stocker G, Quidde J, et al. Randomized controlled trial of S1 maintenance therapy in metastatic esophagogastric cancer—the multinational MATEO study［J］. BMC Cancer, 2017, 17(1): 509516. DOI: 10.1186/s1288501734979. ［9］ Moriya K, Shimizu H, Handa S, et al. Incidence of ophthalmic disorders in patients treated with the antineoplastic agent S1［J］. Gan To Kagaku Ryoho, 2017, 44(6): 501506. ［10］ Qiu MZ, Wei XL, Zhang DS, et al. Efficacy and safety of capecitabine as maintenance treatment after firstline chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation［J］. Tumor Biol, 2014, 35(5): 43694375. DOI: 10.1007/s1327701315745. ［11］ Eren OO, Ozturk MA, Sonmez OU, et al. Safety, feasibility, and efficacy of capecitabine maintenance in patients with advanced gastric cancer: a retrospective study［J］. Am J Ther, 2016, 23(6): e1493e1497. DOI: 10.1097/MJT.0000000000000156. ［12］ Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial［J］. Lancet, 2010, 376(9742): 687697. DOI: 10.1016/S01406736(10)61121X. ［13］ AbdelRahman O, Helbling D, Schmidt J, et al. Treatmentrelated death in cancer patients treated with immune checkpoint inhibitors: a systematic review and metaanalysis［J］. Clin Oncol (R Coll Radiol), 2017, 29(4): 218230. DOI: 10.1016/j.clon.2016.11.007. ［14］ IlhanMutlu A, Taghizadeh H, Beer A, et al. Correlation of trastuzumabbased treatment with clinical characteristics and prognosis in HER2positive gastric and gastroesophageal junction cancer: a retrospective single center analysis［J］. Cancer Biol Ther, 2018, 19(3): 169174. DOI: 10.1080/15384047.2017.1414759. ［15］ Palacio S, LoaizaBonilla A, Kittaneh M, et al. Successful use of trastuzumab with anthracyclinebased chemotherapy followed by trastuzumab maintenance in patients with advanced HER2positive gastric cancer［J］. Anticancer Res, 2014, 34(1): 301306. ［16］ Wll E, Thaler J, Keil F, et al. Oxaliplatin/irinotecan/bevacizumab followed by docetaxel/bevacizumab in inoperable locally advanced or metastatic gastric cancer patients—AGMT_GASTRIC3［J］. Anticancer Res, 2017, 37(10): 55535558. DOI: 10.21873/anticanres.11987. ［17］ Meulendijks D, de Groot JW, Los M, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as firstline treatment of patients with advanced HER2negative gastric cancer: a multicenter phase 2 study［J］. Cancer, 2016, 122(9): 14341443. DOI: 10.1002/cncr.29864. ［18］ Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial［J］. Lancet, 2014, 383(9911): 3139. DOI: 10.1016/S01406736(13)617195. ［19］ Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(11): 12241235. DOI: 10.1016/S14702045(14)704206. ［20］ Di Bartolomeo M, Niger M, Morano F, et al. Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of firstline chemotherapy in patients with advanced HER2 negative gastric or gastroesophageal junction cancers: the ARMANI phase Ⅲ trial［J］. BMC Cancer, 2019, 19(1): 283. DOI: 10.1186/s1288501954983. ［21］ Maron SB, Catenacci DV. Novel targeted therapies for esophagogastric cancer［J］. Surg Oncol Clin N Am, 2017, 26(2): 293312. DOI: 10.1016/j.soc.2016.10.002. ［22］ Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent nonsmallcell lung cancer (JAVELIN solid tumor): doseexpansion cohort of a multicentre, openlabel, phase 1b trial［J］. Lancet Oncol, 2017, 18(5): 599610. DOI: 10.1016/S14702045(17)302401. ［23］ Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an openlabel, phase 1 trial［J］. Lancet Oncol, 2018, 19(1): 5164. DOI: 10.1016/S14702045(17)309002. ［24］ Chung HC, Arkenau HT, Lee J, et al. Avelumab (antiPDL1) as firstline switchmaintenance or secondline therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN solid tumor trial［J］. J Immunother Cancer, 2019, 7(1): 3039. DOI: 10.1186/s4042501905081. ［25］戴韵峰, 郭震浪, 程晶, 等. 中医辨证论治联合化疗治疗晚期非小细胞肺癌的Meta分析［J］. 中国实验方剂学杂志, 2016, 22(2): 180185. DOI: 10.13422/j.cnki.Syfjx.2016020180. ［26］ Wang Q, Wang Q, Wang SF, et al. Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced nonsmallcell lung cancer: a systematic review and metaanalysis［J］. Curr Oncol, 2017, 24(4): e269e276. DOI: 10.3747/co.24.3561. ［27］张朋, 刘苓霜, 姜怡, 等. 病证结合的中医药维持治疗方案干预晚期非小细胞肺癌免疫逃逸的临床研究［J］. 中华中医药杂志, 2018, 33(11): 52345239.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[4]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[5]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[6]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[7]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[8]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[9]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[12]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[13]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[14]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[15]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.